Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

(2022) Lihong Liu et al.   NATURE

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

(2022) Jennifer Hammond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Key dimer interface residues impact the catalytic activity of 3CLpro, the main protease of SARS-CoV-2

(2022) Juliana C. Ferreira et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19

(2022) Yuto Unoh et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

(2022) Sho Iketani et al.   NATURE

Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms

(2022) Laura J. Stevens et al.   Science Translational Medicine

Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19

(2022) Hengrui Liu et al.   Nature Communications

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report

(2022) Shiv Gandhi et al.   Nature Communications

Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites

(2022) Sho Iketani et al.   Cell Host & Microbe

Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir

(2022) Kai S. Yang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5

(2022) Qian Wang et al.   NATURE

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections

(2022) Heba N. Altarawneh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance

(2022) Ala M. Shaqra et al.   Nature Communications

A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part

(2022) Hiroshi Mukae et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes

(2022) Aditya K. Padhi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

V-pipe: a computational pipeline for assessing viral genetic diversity from high-throughput data

(2021) Susana Posada-Céspedes et al.   BIOINFORMATICS

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2

(2021) Wendy P. Painter et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

COVID-19 CG enables SARS-CoV-2 mutation and lineage tracking by locations and dates of interest

(2021) Albert Tian Chen et al.   eLife

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

(2021) Jerald Sadoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

CellProfiler 4: improvements in speed, utility and usability

(2021) David R. Stirling et al.   BMC BIOINFORMATICS

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York

(2021) Medini K. Annavajhala et al.   NATURE

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2

(2021) Agnieszka M. Szemiel et al.   PLoS Pathogens

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

(2021) Angélica Jayk Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

(2021) Robert L. Gottlieb et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

(2021) Anil Gupta et al.   NEW ENGLAND JOURNAL OF MEDICINE

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

(2021) Dafydd R. Owen et al.   SCIENCE

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

(2021) William A. Fischer et al.   Science Translational Medicine

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332

(2021) Yao Zhao et al.   Protein & Cell

SciPy 1.0: fundamental algorithms for scientific computing in Python

(2020) Pauli Virtanen et al.   NATURE METHODS

An Infectious cDNA Clone of SARS-CoV-2

(2020) Xuping Xie et al.   Cell Host & Microbe

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

(2020) Lihong Liu et al.   NATURE

Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19

(2020) Robert L. Hoffman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome

(2020) Chengjin Ye et al.   mBio

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

(2020) David M. Weinreich et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

(2020) Peter Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Conserved Genomic Terminals of SARS-CoV-2 as Coevolving Functional Elements and Potential Therapeutic Targets

(2020) Agnes P. Chan et al.   mSphere

GISAID: Global initiative on sharing all influenza data – from vision to reality

(2017) Yuelong Shu et al.   Eurosurveillance